MedPath

Gonadal Toxicity in Women With Hodgkin Lymphoma

Conditions
Hodgkin Lymphoma
Registration Number
NCT01008735
Lead Sponsor
Gruppo Italiano Studio Linfomi
Brief Summary

The Gruppo Italiano Studio Linfomi has been collecting data on patients with Hodgkin Lymphoma (HL) since 1988. This archive represents a homogeneous series of consecutive patients with HL. The very long follow up and the availability of clinical and treatment data make it feasible to perform a study on the gonadal toxicity related to treatment for HL.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
150
Inclusion Criteria
  • Female patients in complete remission after chemotherapy for Hodgkin lymphoma
  • Age ≥ 18 e < 40 years
  • Previous regular menstrual cycle
  • No previous or concomitant gynecological diseases affecting reproducing function
  • No other chemo-radiotherapy for other neoplasm
  • Written informed consent
Exclusion Criteria
  • none

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
incidence of gonadal toxicity in terms of irreversible amenorrhea and infertility, in women of reproductive age with Hodgkin lymphoma treated with chemotherapy.from end of treatment until date of last contact/visit
Secondary Outcome Measures
NameTimeMethod
role of a prophylactic treatment with oral contraceptives and GnRH analogs in preventing gonadal damagefrom end of treatment until date of last contact/visit

Trial Locations

Locations (1)

Gruppo Italiano Studio Linfomi

🇮🇹

Modena, Italy

© Copyright 2025. All Rights Reserved by MedPath